Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. / Migoya, E M; Bergeron, R; Miller, J L; Snyder, R N K; Tanen, M; Hilliard, D; Weiss, B; Larson, P; Gutierrez, M; Jiang, G; Liu, F.; Pryor, K A; Yao, J; Zhu, L; Holst, Jens Juul; Deacon, C; Herman, G; Thornberry, N; Amatruda, J; Williams-Herman, D; Wagner, J A; SinhaRoy, R.
In: Clinical Pharmacology and Therapeutics, Vol. 88, No. 6, 01.12.2010, p. 801-8.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1
AU - Migoya, E M
AU - Bergeron, R
AU - Miller, J L
AU - Snyder, R N K
AU - Tanen, M
AU - Hilliard, D
AU - Weiss, B
AU - Larson, P
AU - Gutierrez, M
AU - Jiang, G
AU - Liu, F.
AU - Pryor, K A
AU - Yao, J
AU - Zhu, L
AU - Holst, Jens Juul
AU - Deacon, C
AU - Herman, G
AU - Thornberry, N
AU - Amatruda, J
AU - Williams-Herman, D
AU - Wagner, J A
AU - SinhaRoy, R
PY - 2010/12/1
Y1 - 2010/12/1
N2 - The aim of the study was to investigate the effects of a dipeptidyl peptidase-4 (DPP-4) inhibitor, of metformin, and of the combination of the two agents, on incretin hormone concentrations. Active and inactive (or total) incretin plasma concentrations, plasma DPP-4 activity, and preproglucagon (GCG) gene expression were determined after administration of each agent alone or in combination to mice with diet-induced obesity (DIO) and to healthy human subjects. In mice, metformin increased Gcg expression in the large intestine and elevated the plasma concentrations of inactive glucagon-like peptide 1 (GLP-1) (9-36) and glucagon. In healthy subjects, a DPP-4 inhibitor elevated both active GLP-1 and glucose dependent insulinotropic polypeptide (GIP), metformin increased total GLP-1 (but not GIP), and the combination resulted in additive increases in active GLP-1 plasma concentrations. Metformin did not inhibit plasma DPP-4 activity either in vitro or in vivo. The study results show that metformin is not a DPP-4 inhibitor but rather enhances precursor GCG expression in the large intestine, resulting in increased total GLP-1 concentrations. DPP-4 inhibitors and metformin have complementary mechanisms of action and additive effects with respect to increasing the concentrations of active GLP-1 in plasma.
AB - The aim of the study was to investigate the effects of a dipeptidyl peptidase-4 (DPP-4) inhibitor, of metformin, and of the combination of the two agents, on incretin hormone concentrations. Active and inactive (or total) incretin plasma concentrations, plasma DPP-4 activity, and preproglucagon (GCG) gene expression were determined after administration of each agent alone or in combination to mice with diet-induced obesity (DIO) and to healthy human subjects. In mice, metformin increased Gcg expression in the large intestine and elevated the plasma concentrations of inactive glucagon-like peptide 1 (GLP-1) (9-36) and glucagon. In healthy subjects, a DPP-4 inhibitor elevated both active GLP-1 and glucose dependent insulinotropic polypeptide (GIP), metformin increased total GLP-1 (but not GIP), and the combination resulted in additive increases in active GLP-1 plasma concentrations. Metformin did not inhibit plasma DPP-4 activity either in vitro or in vivo. The study results show that metformin is not a DPP-4 inhibitor but rather enhances precursor GCG expression in the large intestine, resulting in increased total GLP-1 concentrations. DPP-4 inhibitors and metformin have complementary mechanisms of action and additive effects with respect to increasing the concentrations of active GLP-1 in plasma.
KW - Adolescent
KW - Adult
KW - Animals
KW - Cross-Over Studies
KW - Dipeptidyl-Peptidase IV Inhibitors
KW - Double-Blind Method
KW - Drug Therapy, Combination
KW - Female
KW - Glucagon-Like Peptide 1
KW - Humans
KW - Male
KW - Metformin
KW - Mice
KW - Mice, Inbred C57BL
KW - Middle Aged
KW - Obesity
KW - Young Adult
U2 - 10.1038/clpt.2010.184
DO - 10.1038/clpt.2010.184
M3 - Journal article
C2 - 21048706
VL - 88
SP - 801
EP - 808
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
SN - 0009-9236
IS - 6
ER -
ID: 33938724